Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activities
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Amortization of Deferred Charges (2022 - 2023)

Acro Biomedical (ACBM) has 2 years of Amortization of Deferred Charges data on record, last reported at $3.1 million in Q2 2023.

  • For Q2 2023, Amortization of Deferred Charges fell 20.48% year-over-year to $3.1 million; the TTM value through Jun 2023 reached $14.9 million, changed N/A, while the annual FY2022 figure was $15.7 million, 105.35% up from the prior year.
  • Amortization of Deferred Charges reached $3.1 million in Q2 2023 per ACBM's latest filing, down from $3.9 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $3.9 million in Q1 2022 and bottomed at $3.1 million in Q2 2023.